Original YOCON Biotechnology
- Research Frontier
After the previous introduction, many of you are likely familiar with YOCON's [Research Frontier] section. YOCON's product system, known for its comprehensiveness, professionalism, and innovation, has helped industrial clients submit numerous clinical cell therapy drug applications, as well as contributed greatly to scientific research. Here, we will continue to share the latest scientific articles and developments, allowing everyone to witness the power of science.
In this series, we will explore a study published in the Stem Cell Research & Therapy journal, a high-quality international journal (IF=7.9) focusing on stem cell therapy and regenerative medicine. The article titled "An efficient protocol to generate placental chorionic plate-derived mesenchymal stem cells with superior proliferative and immunomodulatory properties" utilizes YOCON's serum-free MSC medium (NC0103) to culture various types of MSCs, including CP-MSCs, CV-MSCs, D-MSCs, and UC-MSCs, derived from the placenta and umbilical cord. The study developed an efficient method for generating placental chorionic plate-derived mesenchymal stem cells with superior proliferative and immunomodulatory characteristics, providing strong support for clinical applications.
Related Product
Mesenchymal Stem Cell Serum-Free Medium
- Specifically developed for umbilical cord-derived MSCs, also suitable for MSCs from placental, bone marrow, and dental pulp sources.
- A truly serum-free, pure cytokine culture system with no human or animal origin, making it more suitable for cell therapy IND filing and clinical trial research.
- Superior performance, with MSC surface markers remaining stable through continuous passaging to P20.
- Received FDA Class II medical device registration (510(K) number: K232543), making it the first stem cell culture medium from China to receive such recognition.
01 Research Background
- Mesenchymal stem cells (MSCs), due to their high self-renewal and multidirectional differentiation abilities, low immunogenicity, and immunomodulatory properties, have immense potential in clinical applications.
- Bone marrow is the traditional source of MSCs, but due to the low number of cells, the invasive collection process, and decreased proliferative capacity with age, it is not an ideal source for MSCs.
- However, the growing demand for MSCs in clinical trials necessitates the availability of high-quality, large-scale MSCs, making it necessary to find alternative sources for clinical use.
02 Theoretical Basis
Perinatal tissues, such as the placenta and umbilical cord, are promising sources of MSCs due to their ease of access, non-invasive collection process, and minimal ethical constraints.
Compared to MSCs derived from adult bone marrow or adipose tissue, placental-derived MSCs (P-MSCs) and umbilical cord-derived MSCs (UC-MSCs) are considered to have stronger proliferative and immunomodulatory abilities and lower immunogenicity.
Studies have shown that P-MSCs outperform UC-MSCs in immunomodulatory properties. Therefore, the placenta appears to be a better source for MSCs. Various P-MSCs have been successfully isolated from different anatomical regions of the placenta, including chorionic plate-derived MSCs (CP-MSCs), chorionic villi-derived MSCs (CV-MSCs), amniotic membrane-derived MSCs (AM-MSCs), and decidua-derived MSCs (D-MSCs).
03 Research Approach
The main methods for isolating P-MSCs are enzymatic digestion and explant culture (EC) methods. In enzymatic digestion, tissue fragments are digested with proteases, and the resulting cell suspension is cultured. However, this method can affect the biological properties of MSCs, such as their proliferative capacity, and reduce cell viability due to extended digestion times. Although MSCs obtained through EC have better biological functions, the slower migration of cells from the tissue blocks means longer times to reach confluence.
By combining an initial mild enzymatic digestion reaction with subsequent explant culture, an improved MEC method was developed to generate various P-MSCs from different placental regions in serum-free medium. The study compared its isolation efficiency, cell yield, and proliferative capacity to traditional EC methods, and determined whether the site of tissue harvest affects the functional properties of P-MSCs, including their proliferation, migration capacity, and immunomodulatory effects on macrophages.
04 Research Results
Compared to traditional methods, the MEC method achieved higher yields and shorter primary cell confluence times in serum-free medium.
The harvested cells exhibited MSC characteristics and showed significantly enhanced proliferative capacity.
MSCs derived from the chorionic plate (CP-MSCs) demonstrated superior proliferative and migration abilities compared to other P-MSCs and retained their fetal characteristics during continuous passaging. They also exhibited a stronger ability to modulate macrophages from M1 to M2 polarization.
05 Clinical Outlook
This study developed an efficient, high-yield P-MSC cultivation technique and confirmed the superior characteristics of CP-MSCs, providing new technical support and a theoretical foundation for the clinical application of P-MSCs.
This is a brief interpretation of the research paper. In the upcoming issues, we will explore the research approach and experimental methods in more detail. If you are interested in this field, stay tuned to YOCON’s Research Frontier section, and together, let’s witness the power of science!
